Background : Dilated cardiomyopathy (DCM) is one of the common causes of cardiovascular mortality and morbidity. Some of the angiotensin receptor blockers have been reported to improve survival and left ventricular (LV) function in DCM patients. Fimasartan is a new type of angiotensin receptor blockers (ARBs) with approved indication for hypertension; however, its effect on heart failure has not been investigated. We performed preclinical study in DCM animal model to evaluate an effect of Fimasartan on DCM progression. Method: All animals performed baseline echocardiography and then randomly assigned into 3 groups; daily treated with vehicle (non-treated group (n=6)), 5mg/Kg of Fimasartan (low-dose group (n=6)), and 10mg of Fimasartan (high-dose group (n=10)), respectively. And then, doxorubicin (3mg/kg) was injected intravenously once a week for 6 weeks. Vehecle and Fimasartan were administered via gastric gavage for 8 weeks. Echocardiography was performed in baseline, 6 weeks, and 8 weeks after treatment to confirm the LV systolic function and remodeling. Hemodynamic assessment was performed after echocardiography using the miniaturized conductance catheter system. Result : Survival rate after 8 weeks of treatment were highest in high-dose group (100%), but 75% in low-dose, and 50% in non-treated group (Figure, p<0.05). Echocardiography showed preserved LV systolic function in in high-dose group after 8weeks of treatment (LV EF=727%), but not in non-treated group (Figure2, p=0.002). LV end-systolic and end-diastolic dimension (ESD and EDD) increased progressively in non-treated group; however remodeling was attenuated in low-dose and high-dose group (Figure. p<0.05). Hemodynamic study showed higher dP/dt in high-dose group than non-treated group (p<0.05). Conclusion: Fimasartan improved survival and LV function and attenuated the progression of LV remodeling in rat model of DCM. It shows possibility of Fimasartan as a treatment option for heart failure and should be confirmed in human clinical trials in the future.